vimarsana.com

Latest Breaking News On - Urogen pharma - Page 12 : vimarsana.com

UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments

Both ENVISION and ATLAS Phase 3 trials of UGN-102 met primary endpoints in treating low-grade intermediate-risk non‐muscle‐invasive bladder cancer . Reported record JELMYTO® net product. -Today at 08:05 am- MarketScreener

Earnings Scheduled For August 10, 2023 - Janus Intl Gr (NYSE:JBI), Invivyd (NASDAQ:IVVD)

Earnings Scheduled For August 10, 2023 - Janus Intl Gr (NYSE:JBI), Invivyd (NASDAQ:IVVD)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

UroGen Pharma Ltd Q2 Loss decreases, beats estimates

UroGen Pharma Ltd. (URGN) released Loss for second quarter that decreased from last year and beat the Street estimates. The company's earnings totaled -$24.14 million, or -$1.

UroGen Pharma (URGN) Scheduled to Post Earnings on Thursday

UroGen Pharma (NASDAQ:URGN – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Thursday, August 10th. Analysts expect the company to announce earnings of ($1.13) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link. UroGen […]

Bladder Cancer Market Likely To Exhibit Substantial Growth, Assesses Delveinsight | Leading Companies - Ciclomed, Bristol-Myers Squibb, Cg Oncology, M

Bladder Cancer Market Likely To Exhibit Substantial Growth, Assesses Delveinsight | Leading Companies - Ciclomed, Bristol-Myers Squibb, Cg Oncology, M
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.